Dr. Stein on Blinatumomab for Relapsed/Refractory ALL

Anthony S. Stein, MD
Published: Tuesday, Dec 22, 2015



Anthony S. Stein, MD, professor and staff physician, Hematologic Malignancies and Stem Cell Transplantation Institute, City of Hope, discusses a phase II study examining blinatumomab in relapsed/refractory patients with Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia (ALL).

To be eligible for enrollment, all patients had to have failed on a second-generation tyrosine kinase inhibitor. Several patients also harbored a T3151 mutation, as well as others, Stein adds. The majority of patients failed all effective conventional therapies that are currently available.

When treated with blinatumomab, the overall response rate was approximately 36%.



Anthony S. Stein, MD, professor and staff physician, Hematologic Malignancies and Stem Cell Transplantation Institute, City of Hope, discusses a phase II study examining blinatumomab in relapsed/refractory patients with Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia (ALL).

To be eligible for enrollment, all patients had to have failed on a second-generation tyrosine kinase inhibitor. Several patients also harbored a T3151 mutation, as well as others, Stein adds. The majority of patients failed all effective conventional therapies that are currently available.

When treated with blinatumomab, the overall response rate was approximately 36%.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x